A
Allegro Ophthalmics
Treating vitreoretinal diseases
About Allegro Ophthalmics
Allegro Ophthalmics is pioneering the treatment of ocular diseases through innovative integrin inhibition therapies. The company focuses on developing treatments for conditions such as Dry Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Dry Eye Disease. Allegro's primary clientele includes ophthalmologists and healthcare providers specializing in eye care, as well as patients suffering from these debilitating eye conditions. Operating in the biopharmaceutical market, Allegro leverages cutting-edge clinical research to bring novel therapies from theory to therapy.
The business model of Allegro Ophthalmics revolves around the development and commercialization of its proprietary drug candidates. The company generates revenue through the successful advancement of its drug pipeline, securing partnerships, and potentially licensing its technologies to larger pharmaceutical companies. Allegro's integrin regulating portfolio, particularly its lead candidate Risuteganib, is currently in various stages of clinical trials, showcasing promising results in improving visual function and halting disease progression.
Allegro's commitment to rigorous clinical research and its strategic focus on unmet medical needs position it as a key player in the ophthalmic treatment landscape. By continuously presenting its findings at major ophthalmology conferences, the company maintains a strong presence in the scientific community and keeps stakeholders informed about its progress.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jul 2017 | $11M | $43M | Undisclosed | ↗ |
| GRANTOther financing | Feb 2015 | $2M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Allegro Ophthalmics is 1.3K monthly website visits, up 400% over the last three months. Allegro Ophthalmics's team declined 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Allegro Ophthalmics in the San Juan Capistrano ecosystem
The Allegro Ophthalmics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Hanmi Pharmaceutical
Other known investors1 additional known investor
Caltech, California Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allegro Ophthalmics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allegro Ophthalmics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









